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139 Is the Low Prevalence of Peanut Allergy in Israel Due toHypoallergenic Peanut Products?
S. J. Maleki1, S. L. Hefle2, H. Cheng1, Y. Katz3, G. Du Toit4, G. Lack4;
1Food Allergy Unit, USDA-Agricultural Research Service, New Orleans,
LA, 2Food Allergy Research and Resource Program, University of
Nebraska, Lincoln, NE, 3Sackler School of Medicine,Tel-Aviv Universi-
ty, Assaf-Harofeh Medical Center, Zerifin, ISRAEL, 4Department of Pae-
diatric Allergy and Immunology, Imperial College at St Mary’s Hospital,
London, UNITED KINGDOM.
RATIONALE: In Israel the majority of infants less than 12 months old
regularly consume peanut products in contrast to the UK where infants
avoid peanut products. Previous studies suggest a low prevalence of
peanut allergy in Israel and raise the possibility that the processing of
Israeli peanut snacks renders them hypoallergenic. Therefore, the allergen
content and allergenicity of the most popular peanut products consumed
by children and infants in the UK and Israel were compared to determine
if such differences could explain the variation in the prevalence of peanut
allergy.
METHODS: The total protein content of whole snack products was
determined using LECO analysis and various immunoassays were utilized
to determine the percentage of peanut protein in each product. The prod-
ucts were all normalized according to peanut protein content and subject-
ed to SDS-PAGE, Western blot and Slot blot analysis with anti-peanut,
anti-Ara h 1, 2 and 3 antibodies and pooled serum from peanut allergic
individuals.
RESULTS: Peanut protein levels from Israeli and U.K. products were
found to be between 68-100%. The Ara h 1, Ara h 2 and Ara h 3 proteins
in each peanut product were intact and the levels were comparable. Sim-
ilarly, IgE binding analysis with pooled serum from 9 allergic individuals
was nearly identical when the same amount of peanut protein was used for
each product. 
CONCLUSIONS: The contents of peanut protein, individual major aller-
gens and IgE binding capacity of the popular snacks from Israel cannot
explain the large discrepancies in the prevalence of peanut allergy among
the two countries.
Funding: National Peanut Board and the USDA
140 Effects of ImmuSoy as a Food Supplement for Altering PeanutAllergic Reactions
T. Zhang1, W. Pan2, M. Takebe3, H. A. Sampson1, X. Li1; 1Pediatrics,
Allergy & Immunology, Mount Sinai School of Medicine, New York, NY,
2Surgery, Harvard Medical School, Beth Israel Deaconess Medical Cen-
ter, Boston, MA, 3Nichimo Co., Ltd., Tokyo, JAPAN.
RATIONALE: ImmuSoy is a koji fungus (Aspergillus oryzae) and lacto-
bacteria soybean fermentation product, based on traditional Japanese fer-
mentation technology. It is believed that this unique food supplement is
beneficial for the immune system. We hypothesized that ImmuSoy may
be effective for treating peanut allergy.
METHODS: Peanut allergic mice (C3H/HeJ, n=8-10/group) were fed
ImmuSoy containing chow (0.5 % and 1 %), or regular chow (control) for
4 weeks beginning week 10 following peanut sensitization, and then were
challenged with peanut. Anaphylactic scores, plasma histamine, serum
peanut specific-IgE levels and splenocyte cytokine production to peanut-
stimulation were determined.
RESULTS: All control mice developed anaphylaxis (median score 3.3)
following peanut challenge, in contrast, 50% and 25% of low and high
doses of ImmuSoy treated-mice developed anaphylaxis (median scores
1.0 and 0.33 respectively). The low and high dose ImmuSoy treated-mice
showed 50.4 % and 80.7% reduction respectively in plasma histamine,
and 47.1% and 73.9% reduction respectively in serum IgE levels as com-
pared to untreated mice (p<0.05). Furthermore, IL-4 and IL-5 production
by splenocytes of high dose ImmuSoy-treated mice were reduced by
74.1% and 77.0% whereas IFN- production was increased by 34.8%
compared to control splenocytes.
CONCLUSIONS: ImmuSoy used as a food supplement protects against
peanut-induced anaphylaxis in this model, which is associated with down-
regulation of Th2 responses. This approach might be a potential novel
therapy for peanut allergy.
Funding: Nichimo Co., Ltd., Tokyo, Japan
141 Eliciting Doses (ED) for Peanut in Children With and WithoutPrevious Reactions to Peanut
A. E. Flinterman1, S. G. M. Pasmans1, C. A. F. Bruijnzeel-Koomen1, M.
O. Hoekstra2, A. C. Knulst1; 1Dermatology/Allergology, UMC Utrecht,
Utrecht, THE NETHERLANDS, 2Pediatrics, UMC Utrecht, Utrecht,
THE NETHERLANDS.
RATIONALE: In ED studies patients with serious reactions to peanut are
usually not included. In this study we included all children with peanut
sensitization independent of their history.
METHODS: Thirty two children (10 girls, 22 boys; aged 3.0-15.0 years)
were included based on sensitization to peanut. During elimination, twen-
ty of them experienced an allergic reaction to peanut, of which 8 had seri-
ous respiratory symptoms. Double blind placebo controlled food chal-
lenge (DBPCFC) with peanut was performed using the new international
consensus protocol (Taylor et al, Clin Exp Allergy 2004; 34(5):689-695).
Defatted peanut flour was given in 9 gradually increasing steps ranging
from 10g to 3g. Upon negative challenge an open challenge with 10g
peanuts was performed.
RESULTS: Sensitization to peanut was confirmed in all patients by
specific IgE (<0.35-100 kU/L, mean 24.9) and/or SPT (0-18.4mm,
mean 8.6). From the group without a previous reaction (n=12) 6 (50%)
had a positive DBPCFC. Eliciting doses were 1g (n=3) and 3g (n=3).
From the previously reacting group (n=20), 16 children (75%) devel-
oped a reaction during challenge, including 7 of 8 (88%) children with
serious respiratory reaction to peanut in their history. Eliciting doses in
13 of these 16 children consisted of 10mg (n=2), 100mg (n=2), 300mg
(n=3), 1g (n=5) and 3g (n=1), whereas 3/16 children reacted after the
open challenge. Sensitization between both groups did not significant-
ly differ.
CONCLUSIONS: Children with previous reaction to peanut are more
likely to react during DBPCFC. The ED in this group is up to 100-fold
lower than in patients without previous reactions.
142 Patients Find Low Dose Threshold Challenges Useful in theManagement of Their Peanut Allergy
L. A. Gudgeon1, J. B. Trewin2, K. E. C. Grimshaw2, J. O. Hourihane1;
1University of Southampton, Southampton, UNITED KINGDOM, 2Well-
come Trust Clinical Research Facility, Southampton University Hospital
NHS Trust, Southampton, UNITED KINGDOM.
RATIONALE: In a changing clinical environment, Institutional
Review Boards are uncertain about the clinical benefit that accrues to
volunteers, especially children, from research involving double blind
food challenge (DBPCFC). We examined how much detail volunteers
in a low dose DBPCFC study could recall and its impact on their daily
life.
METHODS: A retrospective telephone survey of 40 subjects in a low
dose DBPCFC study of peanut allergy. Subjects had been told at chal-
lenge about the peanut dose that elicited their reaction, both in mg of
peanut protein and the equivalent amount of peanut kernel.
RESULTS: 31 subjects (76%) were traced. Median interval since chal-
lenge was 26 months (range 12-32). 6 subjects could recall their threshold
dose in mg and 5/6 were correct. 11/16 subjects (4 adults, 7 parent prox-
ies) who could recall the equivalent peanut were correct. The remaining
five subjects (all parent proxies) only erred by one dose (4 reported a dose
lower than the documented dose and 1 a dose higher). 19/27 subjects who
commented felt the challenge had a positive effect on their life, 3 felt it
had a negative effect (all 3 reported heightened awareness, which could be
a protective, positive effect) and 5 reported no effect.
CONCLUSIONS: A food challenge is an important life event and any
recall of detail is usually accurate, but only half the group could recall the
estimated threshold dose of peanut kernel. Most subjects considered the
low dose DBPCFC outcome as having a positive effect on their life.
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